iTeos Therapeutics, Inc. (NASDAQ:ITOS) major shareholder Bioventures 2014 L.P. Mpm sold 45,698 shares of iTeos Therapeutics stock in a transaction that occurred on Friday, September 17th. The stock was sold at an average price of $28.82, for a total transaction of $1,317,016.36. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Bioventures 2014 L.P. Mpm also recently made the following trade(s):
- On Monday, September 20th, Bioventures 2014 L.P. Mpm sold 24,303 shares of iTeos Therapeutics stock. The stock was sold at an average price of $27.49, for a total transaction of $668,089.47.
- On Wednesday, September 15th, Bioventures 2014 L.P. Mpm sold 24,104 shares of iTeos Therapeutics stock. The stock was sold at an average price of $27.80, for a total transaction of $670,091.20.
iTeos Therapeutics stock opened at $26.81 on Tuesday. The company’s fifty day simple moving average is $26.16 and its 200-day simple moving average is $26.37. iTeos Therapeutics, Inc. has a 12 month low of $17.43 and a 12 month high of $47.61. The stock has a market cap of $943.98 million, a P/E ratio of -13.08 and a beta of 2.43.
Several research firms have recently commented on ITOS. Zacks Investment Research upgraded shares of iTeos Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, August 30th. SVB Leerink lowered their price target on shares of iTeos Therapeutics from $56.00 to $55.00 and set an “outperform” rating on the stock in a report on Friday, August 13th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $47.25.
A number of large investors have recently modified their holdings of the stock. Marshall Wace LLP bought a new stake in iTeos Therapeutics in the second quarter worth $3,666,000. Marshall Wace North America L.P. bought a new stake in iTeos Therapeutics in the second quarter worth $5,416,000. Morgan Stanley boosted its holdings in iTeos Therapeutics by 62,469.9% in the second quarter. Morgan Stanley now owns 91,352 shares of the company’s stock worth $2,344,000 after purchasing an additional 91,206 shares in the last quarter. Metropolitan Life Insurance Co NY boosted its holdings in iTeos Therapeutics by 110,800.0% in the second quarter. Metropolitan Life Insurance Co NY now owns 6,654 shares of the company’s stock worth $171,000 after purchasing an additional 6,648 shares in the last quarter. Finally, Boothbay Fund Management LLC bought a new stake in iTeos Therapeutics in the second quarter worth $234,000. Hedge funds and other institutional investors own 83.69% of the company’s stock.
About iTeos Therapeutics
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
Read More: How to execute a trade ex-dividend strategy?
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.